GUIDELINES FOR THE DOSAGE OF NEUROLEPTICS .2. CHANGING FROM DAILY ORAL TO LONG-ACTING INJECTABLE NEUROLEPTICS

被引：22

作者：

SCHULZ, P

REY, MJ

DICK, P

TISSOT, R

机构：

来源：

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | 1989年 / 4卷 / 02期

关键词：

D O I：

10.1097/00004850-198904000-00002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：105 / 114

页数：10

相关论文

共 23 条

[1] AAESJORGENSEN T, 1983, PSYCHOPHARMACOLOGY, V81, P68
[2] THEORETICAL AND PRACTICAL IMPORTANCE OF PLASMA-LEVELS OF HALOPERIDOL - CORRELATIONS WITH CLINICAL AND COMPUTERIZED EEG DATA
DEBUCK, RP
ZELASCHI, N
GILLES, C
DURDU, J
BRAUMAN, H
[J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY, 1981, 5 (5-6): : 499 - 502
[3] DESCHEPPER PJ, 1979, ARZNEIMITTEL-FORSCH, V29-2, P1056
[4] FLUPHENAZINE PHARMACOKINETICS AND THERAPEUTIC RESPONSE
DYSKEN, MW
JAVAID, JI
CHANG, SS
SCHAFFER, C
SHAHID, A
DAVIS, JM
[J]. PSYCHOPHARMACOLOGY, 1981, 73 (03) : 205 - 210
[5] ERESHEFSKY L, 1984, CLIN IMPLICATIONS FL, P1
[6] FORSMAN A, 1976, CURR THER RES CLIN E, V20, P319
[7] FORSMAN A, 1979, BIOL PSYCHIATRY TODA, P949
[8] HANSEN CE, 1976, BRIT J CLIN PHARMACO, V3, P915
[9] HALOPERIDOL KINETICS AFTER ORAL AND INTRAVENOUS DOSES
HOLLEY, FO
MAGLIOZZI, JR
STANSKI, DR
LOMBROZO, L
HOLLISTER, LE
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (04) : 477 - 484
[10] HOLLISTER LM, 1978, CLIN PHARM PSYCHOTHE, P165